Investment Highlights

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biotech company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented two posters at the ESMO IO 2017 (European Society for Medical Oncology – Immuno Oncology) in Geneva, Switzerland (7 – 10 December 2017). [more]

Annual Report 2016
Download PDF

Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

Quarterly Statement as at 30 September 2017

Download PDF

November 9, 2017
Quarterly Statement as at September 30, 2017


Show complete Corporate Calendar.

January 18 - January 20, 2018

ASCO GI Gastrointestinal Cancers Symposium, San Francisco, USA


December 7 - December 10, 2017

ESMO Immuno Oncology Conference, Geneva, Switzerland

Show complete calendar.





Share Subscription Facility with US investor GCF

Further Information

Share Price


Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50

Distribution list

If you would like to receive our press releases, please click here.